Caricamento...
HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
Although multiple myeloma (MM) patients benefit from standard bortezomib (BTZ) chemotherapy, they develop drug resistance, resulting in relapse. We investigated whether histone deacetylase 6 (HDAC6) inhibitor A452 overcomes bortezomib resistance in MM. We show that HDAC6-selective inhibitor A452 sig...
Salvato in:
| Pubblicato in: | Int J Mol Sci |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7866276/ https://ncbi.nlm.nih.gov/pubmed/33572814 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms22031341 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|